The FDA’s removal of REMS requirements for BCMA- and CD19-directed CAR-T therapies marks a pivotal regulatory milestone—reducing administrative burdens and opening the door to broader patient access. But the real opportunity lies in how manufacturers respond to a growing pipeline of CAR-T candidates competing for limited treatment center capacity. As clinical efficacy alone is no longer enough, the ability to operationalize access and scale delivery models will define commercial success.
EVERSANA outlines a three-phase strategy to help manufacturers evolve beyond the traditional Authorized Treatment Center (ATC) model. From optimizing current ATC throughput to piloting hybrid community partnerships and ultimately enabling fully decentralized care, this roadmap empowers companies to turn access into a competitive advantage. Each phase is supported by EVERSANA’s integrated commercialization capabilities—from referral mapping and site readiness to value-based contracting and digital patient support.
Download the full article to discover how EVERSANA can help you unlock the full potential of your CAR-T therapies and make access your strongest strategic asset.
Author
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial…